

Product Name: Recombinant Human IL-18BP (C-Fc)
Catalog #: PHH0884




Summary

Name	IL-18BP/Interleukin-18 binding protein
Purity	Greater than 95% as determined by reducing SDS-PAGE
Endotoxin level	<1 EU/μg as determined by LAL test.
Construction	Recombinant Human Interleukin-18-binding Protein is produced by our Mammalian expression system and the target gene encoding Thr31-Gly194 is expressed with a human IgG1 Fc tag at the C-terminus.
Accession #	O95998-2
Host	Human Cells
Species	Human
Predicted Molecular Mass	44.8 KDa
Formulation	Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Stability&Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

SDS-PAGE image

Product Name: Recombinant Human IL-18BP (C-Fc)
Catalog #: PHH0884



Alternative Names

Interleukin-18-binding protein; Tadekinig-alfa and IL18BP

Background

Interleukin-18-binding protein, also known as Tadekinig-alfa and IL18BP, contains 1 Ig-like C2-type domain. IL18BP is constitutively expressed and secreted in mononuclear cells. IL18BP functions as an IL18 inhibitor. IL18BP binds to IL18, prevents the binding of IL18 to its receptor, and thus inhibits IL18-induced IFN-gamma production. It has been shown that IL18BP may be a promising molecular approach to inhibit neointimal hyperplasia and arteriosclerosis progression following coronary and peripheral angioplasty.

Note

For Research Use Only , Not for Diagnostic Use.